Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 320.50
Bid: 321.00
Ask: 324.00
Change: 5.50 (1.75%)
Spread: 3.00 (0.935%)
Open: 310.00
High: 328.00
Low: 310.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Recession fear hits stocks; Oxford Biomedica rises

Fri, 01st Jul 2022 08:56

(Alliance News) - Stocks in London opened lower on Friday as investors continued to fret over prospects of a recession as central banks raise interest rates.

Comments from central bankers, including Federal Reserve Chair Jerome Powell, suggest they are willing to endure the pain of a contraction as long as they can rein in rising prices.

More positively, Oxford Biomedica shares rose on a new Covid-19 vaccine deal with AstraZeneca.

The FTSE 100 index was down 40.52 points, or 0.6%, at 7,128.76. The FTSE 250 index was down 105.80 points, or 0.6%, at 18,561.70. The AIM All-Share index was down 2.25 points, or 0.3%, at 873.97.

The Cboe UK 100 index was down 0.5% at 711.88. The Cboe 250 was down 0.7% at 16,204.25, and the Cboe Small Companies was flat at 13,277.87.

In mainland Europe, the CAC 40 stock index in Paris was down 0.1%, while the DAX 40 in Frankfurt was down 0.3%.

"The increasing consensus is that central banks, quite simply, misjudged inflation," said Richard Hunter, head of markets at Interactive Investor. "As such, they find themselves in catch-up mode and, as reiterated in the forum earlier this week, they are committed to control inflation even if the impacts become recessionary."

In the FTSE 100, oil company Harbour Energy was the worst performer, down 3.1%, tracking a plunge in oil prices.

Brent oil was quoted at USD108.85 a barrel Friday morning, down sharply from USD114.74 a barrel at the London equities close Thursday amid recession fears.

Abrdn was down 2.5% after Citigroup downgraded the asset manager to 'sell' from 'neutral'.

BT Group was down 1.3% after staff at the telecommunications company voted to strike, union bosses announced Thursday, joining workers in various UK sectors protesting over pay as decades-high inflation erodes wages.

Dave Ward, general secretary at the Communication Workers Union, said BT now faces its first national strike since the company's privatisation in the 1980s after a ballot in favour of walking out. It comes after strike action in recent days by tens of thousands of rail workers in addition to stoppages held by senior criminal lawyers.

Elsewhere, Oxford Biomedica was up 3.2% after the gene and cell therapy developer signed a new three-year agreement with AstraZeneca, which would facilitate potential future manufacturing opportunities for the FTSE 100-listed drugmaker's Covid-19 vaccine.

AstraZeneca was down 0.8%.

The Oxford, England-based company said that the agreement is an extension of the original 18-month supply & development agreement signed back in September 2020 between the two companies.

Under the new agreement, manufacturing of vaccines at Oxford Biomedica's manufacturing facility will be available to AstraZeneca on an as-needed basis beyond 2022.

On Friday, the Japanese Nikkei 225 index closed down 1.7%. In China, the Shanghai Composite lost 0.3%, while the Hang Seng index in Hong Kong was closed for a holiday. The S&P/ASX 200 in Sydney ended down 0.4%.

China's manufacturing sector returned to expansion levels in June, with the easing of Covid restrictions leading to a sharp expansion of output, and the stabilisation of supply chains, data from Caixin and S&P Global showed.

The Caixin general manufacturing purchasing managers' index rose to 51.7 points in June from 48.1 points in May, signalling the first improvement in the sector in four months, as well as the strongest rate of increase since May 2021.

Companies noted the first expansion of output since February, as a result of the return to more normal operations, as well as the reopening of production lines as Covid restrictions were relaxed.

In Japan, the au Jibun manufacturing PMI slowed to 52.7 in June from 53.3 in May, which was the 17th consecutive month of growth.

"The weaker headline reading was partly due to a near-stagnation of new orders. While remaining in expansion territory, the latest increase in sales was only fractional and the slowest in the current nine-month sequence of growth. The slowdown in demand was commonly linked to rising prices and weaker client confidence amid sustained material shortages and delivery delays," au Jibun explained.

The pound was quoted at USD1.2125 early Friday, down from USD1.2157 at the London equities close Thursday.

The euro was priced at USD1.0440, down from USD1.0456. Against the safe haven Japanese yen, the dollar was trading at JPY134.92, lower against JPY135.89.

Gold was quoted at USD1,796.30 an ounce, down from USD1,807.91 late Thursday.

Friday's economic calendar has manufacturing PMIs from the eurozone at 0900 BST and UK at 0930 BST. There is also eurozone inflation at 1000 BST and US PMIs at 1445 BST and 1500 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.